1. Home
  2. BLBD vs NTLA Comparison

BLBD vs NTLA Comparison

Compare BLBD & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLBD
  • NTLA
  • Stock Information
  • Founded
  • BLBD 1927
  • NTLA 2014
  • Country
  • BLBD United States
  • NTLA United States
  • Employees
  • BLBD N/A
  • NTLA N/A
  • Industry
  • BLBD Construction/Ag Equipment/Trucks
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • BLBD Consumer Discretionary
  • NTLA Health Care
  • Exchange
  • BLBD Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • BLBD 1.5B
  • NTLA 1.4B
  • IPO Year
  • BLBD N/A
  • NTLA 2016
  • Fundamental
  • Price
  • BLBD $40.02
  • NTLA $12.12
  • Analyst Decision
  • BLBD Strong Buy
  • NTLA Buy
  • Analyst Count
  • BLBD 7
  • NTLA 17
  • Target Price
  • BLBD $60.64
  • NTLA $56.63
  • AVG Volume (30 Days)
  • BLBD 667.7K
  • NTLA 2.2M
  • Earning Date
  • BLBD 02-05-2025
  • NTLA 02-20-2025
  • Dividend Yield
  • BLBD N/A
  • NTLA N/A
  • EPS Growth
  • BLBD 327.03
  • NTLA N/A
  • EPS
  • BLBD 3.16
  • NTLA N/A
  • Revenue
  • BLBD $1,347,154,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • BLBD $10.68
  • NTLA $52.50
  • Revenue Next Year
  • BLBD $8.58
  • NTLA $0.42
  • P/E Ratio
  • BLBD $12.29
  • NTLA N/A
  • Revenue Growth
  • BLBD 18.92
  • NTLA N/A
  • 52 Week Low
  • BLBD $24.09
  • NTLA $11.61
  • 52 Week High
  • BLBD $59.40
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • BLBD 45.55
  • NTLA 34.53
  • Support Level
  • BLBD $38.30
  • NTLA $11.79
  • Resistance Level
  • BLBD $45.10
  • NTLA $12.45
  • Average True Range (ATR)
  • BLBD 1.89
  • NTLA 0.76
  • MACD
  • BLBD -0.24
  • NTLA -0.08
  • Stochastic Oscillator
  • BLBD 24.87
  • NTLA 13.84

About BLBD Blue Bird Corporation

Blue Bird Corp is an American bus manufacturing company. It has its operations in two segments. The Bus segment involves the design, engineering, manufacture and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. It carries its operations in the United States, Canada, and the rest of the world. The majority of its sales are derived from the United States through its bus manufacturing business.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: